- Home
- MTEM vs ALBT Comparison
MTEM vs ALBT Comparison
Compare MTEM & ALBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEM
- ALBT
- Stock Information
- Founded
- MTEM 2001
- ALBT 2014
- Country
- MTEM United States
- ALBT United States
- Employees
- MTEM N/A
- ALBT N/A
- Industry
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- ALBT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTEM Health Care
- ALBT Health Care
- Exchange
- MTEM Nasdaq
- ALBT Nasdaq
- Market Cap
- MTEM 9.7M
- ALBT 2.9M
- IPO Year
- MTEM N/A
- ALBT N/A
- Fundamental
- Price
- MTEM $0.71
- ALBT $0.20
- Analyst Decision
- MTEM
- ALBT
- Analyst Count
- MTEM 0
- ALBT 0
- Target Price
- MTEM N/A
- ALBT N/A
- AVG Volume (30 Days)
- MTEM 13.4M
- ALBT 639.6K
- Earning Date
- MTEM 11-11-2024
- ALBT 11-12-2024
- Dividend Yield
- MTEM N/A
- ALBT N/A
- EPS Growth
- MTEM N/A
- ALBT N/A
- EPS
- MTEM N/A
- ALBT N/A
- Revenue
- MTEM $25,470,000.00
- ALBT N/A
- Revenue This Year
- MTEM N/A
- ALBT N/A
- Revenue Next Year
- MTEM N/A
- ALBT N/A
- P/E Ratio
- MTEM N/A
- ALBT N/A
- Revenue Growth
- MTEM N/A
- ALBT N/A
- 52 Week Low
- MTEM $0.30
- ALBT $0.16
- 52 Week High
- MTEM $6.48
- ALBT $1.44
- Technical
- Relative Strength Index (RSI)
- MTEM 38.68
- ALBT 42.61
- Support Level
- MTEM $0.31
- ALBT $0.16
- Resistance Level
- MTEM $1.34
- ALBT $0.30
- Average True Range (ATR)
- MTEM 0.14
- ALBT 0.03
- MACD
- MTEM -0.05
- ALBT 0.00
- Stochastic Oscillator
- MTEM 34.48
- ALBT 26.09
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
About ALBT Avalon GloboCare Corp.
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. It focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.